

# Data Fusion and & 21<sup>st</sup> Century Diagnostics

---

*Fused Diagnostics*  
*Integrated Diagnostics*  
*Advanced Analytics*  
*Computational Diagnostics*  
*Personalized Predictive Modeling*

John E. Tomaszewski, MD

Professor and Chair Department of Pathology & Anatomical Science,  
University at Buffalo, State University of New York

# Learning Objectives

- Recognize that informative data can exist in multiple modes and at multiple levels of scale.
- Understand that diagnostics in the future will likely depend on the integration or fusion of data from multiple sources

# Disclosures

- NIH R01CA1365235-01 “Software to allow for multimode, multiscale fused data for pathology and radiology”
- “ Histology based computer assisted diagnostics (HistoCAD) for automated grading of prostate cancer”. Sponsored Research Agreement and licensed software to Bioimagine, closed 4/1/11
- Scientific Advisory Board member, IbRiS Inc., no financial relationships.

# The Collaborative Group

## ***Center for Computational Imaging and Personalized Diagnostics***

Anant Madabhushi, PhD

### Postdocs:

- James Monaco, PhD
- Gaoyu Xiao, PhD
- Jun Xu, PhD

### Graduate Students:

- Jonathan Chappelow
- Scott Doyle
- Satish Viswanath
- Pallavi Tiwari
- George Lee
- Shannon Agner
- Ajay Basavanahally
- Rob Toth
- Andrew Janowczyk
- Akshay Shridar
- Najeeb Chowdhury
- Sahir Ali
- Rachel Sparks

### Undergraduate Students

- Pratik Patel
- Elaine Yu

### Clinical Collaborators

- Michael D. Feldman, MD, PhD
- John E Tomaszewski, MD
- Mark Rosen, MD, PhD
- Shridar Ganesan, MD, PhD
- Nicholas Bloch, MD
- Steven Master, PhD, MD
- John Kurhanewicz, PhD



John E. Tomaszewski, MD



# “Personalized Medicine”

---

## **Form 1:**

Targeted Therapies Directed at Genetic Variations-Pharmacogenomics

## **Form 2:**

Cellular Engineering and Vaccine Therapy

## **Form 3:**

Fused Diagnostics

# Personalized Medicine Form 1

---

## Pharmacogenomics:

Genomewide RNA expression, DNA copy-number and sequence analyses, and microRNA and proteomic profiling — have the potential to allow individualized selection of treatment as determined by the characteristics of the patient and the tumor.

The NEW ENGLAND JOURNAL of MEDICINE

## EDITORIAL



# Personalized Medicine and Inhibition of *EGFR* Signaling in Lung Cancer

Adi F. Gazdar, M.D.

# EGFR Mutations and Response to TK Inhibitors

---

- Mutations in the tyrosine kinase domain of EGFR result in ligand independent gene activation
  - Deletion of a conserved sequence in exon 19 of EGFR
  - Point mutation in exon 21 of EGFR (L858R)
- The nonrandomized European study by Rosellet al. shows the feasibility of large-scale screening for *EGFR* mutations in patients with advanced non–small-cell lung cancer for selection for *erlotinib* therapy.



# EGFR Mutations and Response to TK Inhibitors

---

- Many confounders
  - Role of copy number
  - Not all mutations with same effect
  - Activating mutations in KRAS confer resistance
  - Response vs. survival

# Personalized Medicine Form 2

---

## Cellular and Vaccine Engineering:

- Using autologous cells as a target for cellular engineering and reconstitution of patient with these modified cells for a desired specific therapeutic effect.
- “It doesn’t get more personal than using your own cells to cure your disease”



# Personalized Rx for HIV

Carl June et al , U of Pa and Sangamo Bioscience

---

- 1% of Caucasians are resistant to HIV infection
- Mutation in CCR5 which encodes receptor on CD4 T cells needed for HIV to infect these cells
- Zinc finger targeting endonucleases to the CCR5 gene with a yield of CCR5-ve cells that are resistant to HIV infection
- Clinical trials underway

# The Digital Transformation of Glass


## *One Element of Fused Diagnostics*

- Virtual slides
- ROI finding algorithms
- Automated assistive analysis
- Computational biology

# Developments in microscope-based pathology



1700's	Microscopy
1850's	Hematoxylin + Cell theory of disease and cancer (Virchow)
1870's	Eosin
1890's	Formaldehyde
1940's	Immunohistochemistry (direct fluorescence)
1970's	In-situ hybridization (radioactive DNA)
1990's	The computer

# Quantitative Histocytometry



# Multi-Parameter IHC Demonstration with ER, PR, and Her2

Classify tissue with machine learning algorithms, segment cellular compartments, extract spectrally unmixed signals from associated compartments, and export per-cell protein expression.



3-D scatter plots show multi-parameter data extracted from individual cells. Note distinct clusters. Cell data can be assessed with cluster or quadrant analysis, commonly used in flow cytometry for phenotyping (double negative, single positive, double positive, etc.)




# *Quantitative Analysis* *Machine Vision and Learning* *Computer Assisted Diagnosis ( CAD)*



# A Challenge

## Identifying Significant Prostate Cancer



Gleason Grading Identifies  
Five Primary Histopathological  
Patterns of Gland Growth  
( Micron Resolution Imaging)




# Pattern 3

vs.

# Pattern 4/5



# Gleason Sum is Strong Predictor of Clinical Progression



Gleason  
Sum 6

Gleason  
Sum >7

Pinto et al. Urol Int  
7:202-208, 2006




# Can CAD be Used to Find Gleason Pattern 4 CAP ?

---


Find the Neoplastic Glands

**A predicate structure:**

Computer Assisted  
Gland Segmentation  
Focused on interior  
gland lumens and  
centroid of each gland



# Segmenting Glands



**Figure 2:** Results of the automatic segmentation algorithm (blue contours – lumen boundary, black contours -- inner boundary of the nuclei of the epithelial cells surrounding the gland). Shown from left to right are example images of benign epithelium, intermediate-, and high grade cancer.


# Classification of Individual Glands

- Leverages two features
  - Gland size , malignant glands are “microacini”
  - The tendency for proximate glands to share the same class
  - This spatial dependency is modeled using a Markov prior
    - Describes the local inter-site dependencies of a random process
    - “Cancer is clonal”




# Region finding in whole mount


Automated region growing gland segmentation algorithm




Gland  
Segmentation



Gland Classification




Boundary Aggregation



Markov Random Field Iteration

Monaco J., et al,  
“Detection of  
prostate cancer  
from whole-mount  
histology images  
using Markov  
random fields”,  
MICCAI, NY, 2008

# Overview of CaP Detection Algorithm



Gland  
Segmentation




Gland  
Classification



Markov Random  
Field Iteration



# CAD Results





Gland  
Segmentation

Gland  
Classification

PPMM

Potts























# Can CAD be Used to Find Gleason Pattern 4 CAP ?


## Establish Informative Quantitative Features

Feature Type	Number of features	Gleason Feature
Nuclear arrangement	25	Nuclear proliferation and infiltration
Graph Features	24	None
Gland Morphology and Architecture	44	Gland differentiation and organization
Texture (Statistical, Haralick, Gabor)	483	None

Doyle S, Hwang M, Shah K, Madabhushi A, Feldman M, Tomaszewski J. IEEE, 2007

	Original Image	Sum Entropy	Average	Gabor Filter	Difference Entropy
Grade 3					
					
Grade 4					
					


# Graph Embedding





# An Image Analysis Approach to CAP Grading

## *Texture Features Examining Pixels*



## *Geometric Features Interrogating Nuclei or Glands*

# “The Curse of Multidimensionality”



---

- In Large Multidimensional Space One Can Always Find Multiple Solutions to a Two Class Problem ( CAP or Not CAP)
- In Order to Avoid This Multiplicity of Solutions One Must Reduce the Dimensions of the Data Used for Classification
- Manifold Learning Methods Reduce the Dimensionality of a Data Set from  $N$  Dimensions to  $M$  Dimensions where  $N \gg M$

# Dimensionality Reduction Mapping Functions

Non-linear data dimensionality reduction, unlike linear methods (PCA) -- object proximity is preserved.

- Locally Linear Embedding
- Isometric Mapping
- Spectral Clustering



Investigating manifold learning schemes for analyzing various very high dimensional biomedical data.





# Dimensionality Reduction Methods

---

- Linear
  - **Principle component analysis**
- Non-Linear
  - **Graph Embedding**
    - **Preserves geodesic distances between images**
    - **Transforms high dimensionality dataset into low-dimensionality space**

## *Non-linear mapping functions: Graph Embedding*


- GE allows for projecting data into reduced dimensional space.
- SVM classifier applied in reduced dimensional space.



*Shi et al, PAMI 1998*




# Grading Prostate Carcinoma





# Graph Embedding Analysis of CAD Data with Dimensionality Reduction and Separation of Gleason Patterns 3 and 4



# Breast Cancer Tissue Grading

- Aim: Quantify tissue structures to distinguish Bloom-Richardson grades of breast cancer





Original Image

Voronoi Diagram





Delaunay Triangulation

Minimum Spanning Tree

High  
Grade




Low  
Grade








# Visualizing Breast Graph Features



**Low Grade**





**High Grade**



# Image-based Risk Score (IbRiS)

- **Aim:** Create an Image-based Risk Score to predict recurrence of ER+ breast cancer




## Recurrence via gene assay

Paik et al., A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. N Engl J Med 2004 351: 2817-2826


## Recurrence via histology grade

Badve, Sunil S., et al., "Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory," J Clin Oncol 2008 26: 2473-2481

# Components of IbRiS




**Automated Nuclei Detection**



**Graph Features Calculated**

# Obtaining IbRiS from Graph Features





Basavanahally, A, Xu, J, Madabhushi, A, Ganesan, S, "Computer-aided prognosis of ER+ breast cancer histopathology and correlating survival outcome with Oncotype DX assay," Biomedical Imaging: From Nano to Macro, pp.851-854, 2009.







# Comparing IbRiS to Genomic Assay

Breast cancer Grade  
based  
discrimination



Oncotype Dx







# **ANOTHER USE CASE FOR QUANTITATIVE HISTOMORPHOMETRY:**

## **PREDICTING SURVIVAL IN HPV OROPHARYNGEAL TUMORS**





# Oropharyngeal Dataset

- HUGE TMAs (each around 11000 x 13000)
- p16+ Oropharyngeal SCC TMAs
- 26 Progressors, 124 Non progressors





# CELL CLUSTER GRAPHS




# How to Meet Diagnostic Challenges of the Future: An Opinion

---


- In Finance , the Axiom is  
“ Follow the Money
- In Medicine .....  
“Follow the Data”

# Characteristics of Data Used in the Diagnostics of the *Future*

- Extremely Large and Quantitative Data Sets
- Require Dimensionality Reduction
- Machine Learning
- Scaled Data
- Different Types of Data Converge – “Fused Diagnostics”



**Path Image Data 2 GB**



**Microarray Data30K = 7.5 MB**




# Data is “Scaled”

---

- There is Informative Data at Every Resolution of Examination
- Informative Data at Each Level of Resolution can be Mapped to the Other Levels.
- The Data at Each Level of Resolution has Unique Attributes

**OPTICAL *1x* MAGNIFICATION RESOLUTION=  $10^{-3}\text{m}$**

**TEXTURE & COLOR  
VARIGATION  
SUSPICIOUS for CAP**



**4T MR**

**T2**


**EX-VIVO**

***1x MAGNIFICATION***

**RESOLUTION= $10^{-4}\text{m}$**


**HYPODENSE**

**AREA INTERRUPTING  
NORMAL CURVILINEAR  
GLAND ARCHITECTURE  
DIAGNOSTIC of CAP  
( mostly)**




**OPTICAL**  
**200X MAGNIFICATION**  
**RESOLUTION=10<sup>-7</sup>m**

**HAPHAZZARD**  
**PATTERN of**  
**INFILTRATING**  
**MICROACINI**  
**DIAGNOSTIC of**  
**CAP GLEASON**  
**PATTERN 3**





**Figure 1: Frequency Plot of copy number aberrations for all 21 samples**




**CGH DATA GENOMIC ANALYSIS**  
***RESOLUTION =  $10^{-7}$  to  $10^{-9}$***




# MS2 Spectra from Paraffin Tissue of CAP

**Fatty Acid  
Synthase in  
CAP**





**Mass Spec Protein Analysis *Resolution* =  $10^{-10}$**

**Caldesmon-1 in  
Benign Stromal  
Hyperplasia**




# Combination of Interpretation






## Combination of Data






**Generalized Fusion Framework =**  
Transforms of data which reduce dimensions but keep links before classifier




# Multimodal Data Converge: A General Fusion Framework Pilot Data




- **Aim:** Fuse image and proteomic features to identify patients with high risk of recurrence



# Generalized Fusion Framework




# Visualizing Graph, Protein, Fused Data




(a)

**Graph-based  
Features**



(b)

**Proteomic  
Features**



(c)

**Fused Feature  
Space**



# Chiseling out Pathology's Place in 21<sup>st</sup> Century Diagnostics ( it's about the analytics)


John E. Tomasz






# Core Philosophy

## Multi-modal data Integration


### Personalized Medicine Form 3 =



## A decorative graphic at the bottom of the slide. It features a series of concentric, overlapping circles or rings. The top half of the graphic is a solid blue color, while the bottom half transitions into a white background. The circles are composed of various shades of blue and white, creating a sense of depth and movement.






# Convergence of Large, Diverse, Scaled Data Streams



# Vetted by Domain Knowledge Expertise



## Integrating Information in Disease x Outcome Categories




## Facilitated by Machine Learning

10-10

***Fused Diagnostics  
Integrated Diagnostics  
Advanced Analytics  
Computational Diagnostics***

***Personalized Predictive Modeling  
(Precision Diagnostics)***





# Evolutionary Implications of “Precision Diagnostics” for the Practice of Pathology



**Personalized Medicine/Molecular Diagnostics**



**Digital Pathology/Telepathology**



**Consultative Role**



**Reward/Pay for Reduction in Unnecessary Testing**




**Diagnostic Wing of the Medical Home**



**Direct Patient Care**

*“Change is the law of life. And those who look only to the past or present are certain to miss the future.”*

*John F. Kennedy*





# Thank You !